Federal regulators in the United States are pushing harder than ever to reduce and eventually replace animal testing in drug and chemical safety assessments. The FDA has released draft guidance targeting non-human primate testing for monoclonal antibodies, while the EPA has outlined a strategy to cut vertebrate animal use in chemical evaluations. Yet for all the momentum, the replacement technologies collectively known as New Approach Methodologies, or NAMs, still lack the validation record needed to fully stand in for live-animal studies, leaving regulators caught between ethical ambition and scientific caution.
FDA Targets Primate Testing for a Major Drug Class
Monoclonal antibodies are among the fastest-growing categories of pharmaceuticals, used to treat cancers, autoimmune disorders, and infectious diseases. Testing these drugs has long required studies on non-human primates, but the FDA released draft guidance on reducing primate testing for this drug class, developed in collaboration with the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) and the National Institutes of Health. The agency also scheduled a public workshop for July 2025 to gather feedback from scientists, drugmakers, and advocacy groups on how to refine the guidance before it becomes final.
The broader direction was captured in reporting by Nature Biotechnology, which framed the FDA’s position as one where animal studies should become the exception rather than the norm. That framing matters because it signals a shift in regulatory philosophy, not just a procedural tweak. If the agency follows through, drug sponsors submitting applications for new monoclonal antibodies could rely more heavily on human cell-based assays, computer models, and organoids rather than primate studies during early development.
For companies, the draft guidance is both an opportunity and a challenge. It encourages sponsors to justify any remaining primate studies with clear scientific rationales and to consider stepwise approaches in which NAMs screen candidates before any in vivo work. But it also leaves open the question of how much NAM data will be enough, especially for first-in-human trials where regulators tend to be risk-averse. Until final guidance is issued and a few high-profile products successfully navigate the new pathway, many firms are likely to hedge by running at least some traditional animal studies in parallel.
Congress and Agencies Build a Legal Foundation
The regulatory push did not appear out of nowhere. The FDA Modernization Act 2.0, passed as S.5002 during the 117th Congress, updated statutory language around nonclinical tests so that drug submissions can rely on in vitro and in silico methods rather than strictly animal tests. The law did not ban animal testing outright. Instead, it removed the legal assumption that animal data was the only acceptable evidence, opening the door for alternatives without mandating them.
On the chemical safety side, the EPA released its New Approach Methods Work Plan, laying out how the agency intends to reduce vertebrate use while maintaining its statutory obligations and protecting public health. The plan describes how different program offices, from pesticides to industrial chemicals, will identify candidate tests for replacement, run pilot projects, and build internal expertise in interpreting NAM data.
The EPA also published a report in September 2024 as part of its broader strategy to reduce animal testing, assessing which existing authorities can already support non-animal data. In that document, the agency’s pesticides office described how it is implementing a phased approach to integrating NAMs into risk assessments. According to the EPA, many rules already allow room for non-animal evidence, though the agency stressed that scientific rigor and explicit acknowledgment of limitations remain essential before new methods can be widely adopted.
A point of political tension has emerged around the EPA’s trajectory. According to a January 2026 agency press release, Administrator Zeldin resumed efforts to eliminate animal testing, claiming the Biden administration had halted the phase-out. That account conflicts with the September 2024 report the EPA published under the prior administration, which itself advanced a strategy to reduce animal use. The competing narratives suggest the policy direction has bipartisan support in principle, even as the two administrations dispute credit and pace.
What NAMs Can and Cannot Do Today
The replacement tools themselves are real but uneven. New approach methods include lab-based cell tests and 3D models such as organoids, which are mini organs grown from human cells, as well as computational simulations that predict how a compound will behave in the body. One of the NAMs with the strongest track record is the Ames test, an in vitro assay for mutagenicity that has been widely accepted as an industry standard since 2021. But the Ames test addresses a narrow question: whether a substance damages DNA. Most drug safety evaluations require answers to dozens of different biological questions, from organ toxicity to immune response, and no single NAM or even a battery of them can yet replicate the full picture that a living organism provides.
A peer-reviewed analysis published by PMC acknowledged that replacing animal testing through NAMs holds promise for developing cheaper and safer drugs, but warned that phasing out in vivo studies too quickly without a solid plan raises safety and effectiveness concerns. The core problem is validation. Regulators need proof that a new method predicts human outcomes at least as reliably as the animal test it replaces, and generating that proof takes years of side-by-side comparison data that, for most NAMs, does not yet exist at scale.
Validation is further complicated by the diversity of regulatory questions. A NAM that works well for skin irritation may not be informative for developmental toxicity or chronic neurotoxicity. Agencies therefore tend to accept NAMs piecemeal, for specific endpoints and contexts of use, rather than as blanket replacements. That incrementalism frustrates animal welfare advocates but reflects the reality that even traditional animal models have known gaps, and regulators are reluctant to swap one imperfect system for another without clear evidence of improvement.
International Pressure Adds Urgency
The United States is not acting in isolation. The European Commission is preparing a roadmap toward phase-out of animal testing for chemical safety assessments, a process tied to the Commission’s response to citizen initiatives and parliamentary resolutions. European regulators are exploring how NAMs, combined with existing exposure limits and real-world monitoring, could eventually replace many vertebrate tests under chemicals legislation, though they similarly emphasize the need for robust validation.
As Europe moves, U.S. regulators face both competitive and diplomatic pressure. If NAM-based strategies become embedded in European market access rules, multinational companies will push for harmonized standards to avoid duplicative testing. At the same time, divergent approaches could create trade frictions, with one region demanding animal data that another seeks to phase out. International bodies and scientific consortia are therefore working to align validation frameworks, but those efforts are still in early stages.
Public Participation and Enforcement in a Transition Era
For the public, the shift toward NAMs may feel abstract, but several tools make the process more tangible. Members of the public can track and comment on proposed regulations and guidance that affect animal testing through the federal portal at Regulations.gov, where agencies post draft policies, supporting science, and responses to stakeholder input. Comment periods on NAM-related proposals often draw submissions from patient groups, animal welfare organizations, and industry, highlighting the trade-offs regulators must navigate.
Environmental enforcement also intersects with the animal testing debate. Companies that mishandle chemicals or violate permit conditions can face scrutiny through the EPA’s online system for reporting violations, which allows communities to flag potential noncompliance. Stronger enforcement of existing pollution controls can, in some cases, reduce the need for additional toxicity testing by limiting exposures at the source, though it does not eliminate the need for premarket safety data.
Language access is another piece of the puzzle. The EPA’s Spanish-language portal, available at EPA en español, provides information on chemical safety, health risks, and regulatory actions for Spanish-speaking communities that are often disproportionately exposed to hazardous substances. As NAMs are incorporated into risk assessments and regulatory decisions, ensuring that explanations of these new methods are accessible across languages and literacy levels will be crucial for maintaining public trust.
A Measured Path Forward
Despite political rhetoric about “ending animal testing,” federal agencies are moving cautiously. The FDA’s primate guidance and the EPA’s NAMs work plan mark clear steps toward fewer animal studies, but both institutions stress that human safety remains the overriding priority. In practice, that means a long period in which NAMs expand their footprint while traditional animal tests persist as backstops for high-risk decisions.
Advocates for rapid change argue that the status quo inflicts unnecessary suffering and can mislead science when animal models fail to predict human responses. Skeptics counter that premature abandonment of animal data could expose patients and communities to unforeseen harms. For now, regulators are trying to steer a middle course: encouraging innovation, codifying legal flexibility, and investing in validation, while keeping the option of animal testing open where the science demands it.
How quickly that balance shifts will depend on the pace of technological progress and the accumulation of real-world case studies in which NAMs successfully replace animal tests without compromising safety. As those examples grow, the ethical and scientific arguments for live-animal studies are likely to weaken. Until then, the United States is engaged in a careful, contested transition, one that aims to reconcile humane treatment of animals with the equally pressing obligation to protect human health and the environment.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
